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Background: Lynch Syndrome (LS) is a familial cancer syndrome with a high prevalence of
colorectal and endometrial carcinomas among affected family members. Clinical criteria,
developed from information obtained from familial colorectal cancer registries, have been
generated to identify individuals at elevated risk for having LS. In 2007, the Society of
Gynecologic Oncology (SGO) codified criteria to assist in identifying women presenting
with gynecologic cancers at elevated risk for having LS. These criteria have not been
validated in a population-based setting.
Materials and Methods: We retrospectively identified 412, unselected endometrial cancer
cases. Clinical and pathologic information were obtained from the electronic medical record,
and all tumors were tested for expression of the DNA mismatch repair proteins through
immunohistochemistry. Tumors exhibiting loss of MSH2, MSH6 and PMS2 were
designated as probable Lynch Syndrome (PLS). For tumors exhibiting
immunohistochemical loss of MLH1, we used the PCR-based MLH1 methylation assay to
delineate PLS tumors from sporadic tumors. Samples lacking methylation of the MLH1
promoter were also designated as PLS. The sensitivity and specificity for SGO criteria for
detecting PLS tumors was calculated. We compared clinical and pathologic features of
sporadic tumors and PLS tumors. A simplified cost-effectiveness analysis was also
performed comparing the direct costs of utilizing SGO criteria vs. universal tumor testing.
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Results: In our cohort, 43/408 (10.5%) of endometrial carcinomas were designated as PLS.
The sensitivity and specificity of SGO criteria to identify PLS cases were 32.7 and 77%,
respectively. Multivariate analysis of clinical and pathologic parameters failed to identify
statistically significant differences between sporadic and PLS tumors with the exception of
tumors arising from the lower uterine segment. These tumors were more likely to occur in
PLS tumors. Cost-effectiveness analysis showed clinical criteria and universal testing
strategies cost $6,235.27/PLS case identified and $5,970.38/PLS case identified,
respectively.
Conclusions: SGO 5-10% criteria successfully identify PLS cases among women who are
young or have significant family history of LS related tumors. However, a larger proportion
of PLS cases occurring at older ages with less significant family history are not detected by
this screening strategy. Compared to SGO clinical criteria, universal tumor testing is a cost
effective strategy to identify women presenting with endometrial cancer who are at elevated
risk for having LS.
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Introduction
Lynch Syndrome – Definition and Clinic Based Screening Criteria
Lynch Syndrome (LS), formerly known as hereditary non-polyposis colorectal
cancer (HNPCC), is a hereditary cancer syndrome characterized by an elevated
prevalence of endometrial and colorectal carcinomas, and to a lesser degree other Lynch
Syndrome associated tumors (LATs), among affected family members. In 1895,
pathologist Aldred Warthin at University of Michigan observed a family with a
significant prevalence of stomach, uterine, and small intestinal tumors. The male
proband, whose index cancer was an upper gastrointestinal tumor, had 10 children and 48
relatives within a three-generation pedigree of which 17 had a diagnosis of cancer during
their lifetimes (1). Through his work and subsequent study by Henry Lynch at Creighton
University, the hereditary cancer syndrome now known as Lynch Syndrome was
characterized (1,2).
The rarity of affected families present in any given region made this syndrome
difficult for a single investigator to study epidemiology, disease natural history, and
genetics. In 1990, the International Collaborative Group on Hereditary Non-Polyposis
Colorectal Cancer, consisting of thirty experts representing eight different countries, met
in Amsterdam to create criteria for future studies designed to investigate the underlying
molecular and genetic basis of the disease (3). In 1997, the working group modified the
Amsterdam criteria to include extracolonic tumors, such as endometrium, stomach,
ovaries, small bowel, ureter, renal pelvis, brain, and hepatobiliary tract (4). These
criteria, summarized in Table 1, ultimately led to the association of LS with germline
mutations in DNA mismatch repair (MMR) genes.
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In addition to the international working group establishing criteria to identify
individuals with HNPCC, the National Cancer Institute (NCI) also developed criteria to
address some of the weaknesses in the original Amsterdam Criteria. These weaknesses
include the role of extracolonic tumors, probands with small families, and
clinicopathologic characteristics associated with LS tumors (5). These criteria,
summarized in Table 1, were also revised subsequently to include results of molecular
diagnostic tests such as microsatellite instability testing (6).
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Table 1. Summary of Amsterdam and Bethesda Criteria for the Evaluation of LS
Amsterdam Ia
(All criteria must
be met)
At least 3 relatives
with CRC, one
must be a firstdegree relative of
other 2.
FAP has been
ruled out

Two affected
generations
At least one of
CRC cases occurs
at < age 50

Amsterdam IIb
(All criteria must
be met)
At least 3
relatives with a
LS-associated
cancer, one
should be a FDR
of the other 2
FAP has been
ruled out

Bethesdac

Revised Bethesdad

Proband with 2 LSrelated cancers,

CRC at age < 50

Proband with CRC and
an FDR with CRC
and/or LS-related cancer
and/or a colorectal
adenoma; one of cancers
diagnosed at age <45 or
adenoma diagnosed at
age < 40
Two affected
CRC or EC diagnosed at
generations
age < 45
At least one LS- Right-sided CRC with an
associated cancer undifferentiated pattern
should be
on histopathology
diagnosed < age diagnosed at age < 45
50
Individuals with signetring-cell-type CRC
diagnosed age < 45

Synchronous,
metachronous or
other LS related
tumors

MSI-H CRC in a pt
<60
CRC in ≥ 1 first
degree relatives
with an LS related
tumor, one
occurring at age <50
CRC in ≥ 2 first- or
second-degree
relatives with LSrelated tumors

Individuals with
adenoma diagnosed at
age < 40
Any individual meeting
Amsterdam Criteria
a:(3)
b:(4)
c:(5)
d:(6)

1: CRC - colorectal cancer
2: FAP - familial adenomatous polyposis
3: FDR - first degree relative
4: EC - endometrial cancer
5: MSI-H – microsatellite instability high
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Computer-based clinical prediction models emerged in the 2000’s that attempted
to provide a proband’s individual risk for having a germline DNA MMR mutation.
These risk calculators include PREMM1,2,6, MMRPredict, and MMRPro (7-9). For each
of these models, the original research population consisted of probands presenting with
CRC and included the model’s ability to predict germline mutations in three of the four
DNA MMR genes (MLH1, MSH2, and MSH6). The area under the receiver-operator
curves in the validation studies was greater than 0.8 in each model, indicative of a
favorable predictor. These models did not address probands presenting with other LATs
nor did they evaluate the model’s ability to predict germline mutations in PMS2.
Given the favorable results from these results in predicting MLH1, MSH2 and
MSH6 mutations among probands presenting with CRC, a validation study among EC
probands was initiated (10). These prediction models were evaluated using a populationbased cohort consisting of 563 unselected endometrial cancer cases as well as a high-risk,
clinic-based cohort consisting of individuals from 129 families enrolled in the Colon
Cancer Family Registry (11). These 3 prediction models had AUCs < 0.8 in both the
population-based cohort and high-risk, clinic-based cohorts and were therefore deemed
less useful tools in the EC population.
In 2007, the Society of Gynecologic Oncology (SGO) published a statement on
risk assessment for inherited cancer syndromes among gynecologic cancer probands (12).
This expert panel deemed genetic risk assessment for individuals with a 5-10% likelihood
of having a germline mutation as reasonable and asserted that an individual with a 2025% possibility of a germline mutation should undergo risk assessment. The committee
published criteria corresponding to the 5-10% and 20-25% risk groups (Table 2). The
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20-25% criteria resemble Amsterdam II criteria, and the 5-10% criteria resemble the
revised Bethesda guidelines. Ryan et al. investigated the performance of these criteria in
a cohort of 76 EC cases from familial cancer registries at Mount Sinai Hospital and in
British Columbia with a known LS germline mutation. The mean age at diagnosis of EC
in their cohort was 47.3 years, and 28/76 (36.8%) were diagnosed at age greater than 50.
They found that SGO 20-25% criteria correctly identified 71% of individuals with a
known LS germline mutation, and the 5-10% criteria correctly identified 93% of
mutation carriers. The 20-25% criteria best identified MSH2 mutations with a 78%
detection rate; however, the detection rates for MLH1 and MSH6 were 61% and 50%,
respectively. The 5-10% criteria performed equally well in the detection of MLH1 and
MSH2 mutations and had a detection rate of 94%, but only had an 88% detection rate for
identifying MSH6 mutations. There were no known PMS2 mutation carriers in this
cohort (13). To date, these criteria have not been validated in a population-based setting.
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Table 2. Society of Gynecologic Oncology (SGO) Criteria for those at 5-10%
and 20-25% risk of having a germline mutation in MLH1, MSH2, MSH6, or
PMS2 (12).
SGO 5-10% Criteria
SGO 20-25% Criteria
EC or CRC diagnosed before age 50 Probands meeting Amsterdam II
Criteria
EC or OC with a synchronous or
Synchronous or metachronous EC
metachronous CRC or other LAT at or CRC, first cancer occurring
any age
before age 50
EC or CRC and a first degree
relative with LAT diagnosed before
age 50

Synchronous or metachronous OC
or CRC, first cancer occurring
before age 50

EC or CRC and ≥ 2 first or second
degree relatives with LATs

CRC or EC with tumor testing
suggestive of LS (IHC or MSI-H)

Proband with first or second degree
relatives who meet these criteria

First or second degree relative with
a known germline mutation

EC: Endometrial Cancer
CRC: Colorectal Cancer
OC: Ovarian Cancer

LAT: Lynch Syndrome associated tumor
MSI-H: Microsatellite Instability-High
IHC: Immunohistochemistry
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Published data suggest that women with EC and mutations in PMS2 and MSH6
are often older with less extensive family histories of CRC or other LATs (14,15). In a
study by Goodfellow et al., endometrial cancers were evaluated in a population-based
fashion to characterize the role of MSH6 mutations in endometrial cancer. In their cohort
of 441 unselected endometrial cancer cases an MSH6 mutation was identified in 1.6%
(7/441). The median age at diagnosis for these carriers was 53.6 years (range: 45-71), and
5/7 cases occurred after age 50 (16).
Bonadona et al. evaluated cancer risk in a cohort of 537 LS germline mutation
carriers enrolled in the French Estimation des Risques de Cancer chez les porteurs de
mutation des genes MMR (ERISCAM) study. The LS cases in this cohort consisted of
248 MLH1, 256 MSH2 and 33 MSH6 mutation carriers. In their examination of the
lifetime cancer risks for MSH6 carriers, they found that the cumulative risk for 70 years
of age for CRC was 12%, EC 21%, ovarian cancer 1% and 0% for stomach, small bowel,
and biliary tract. These risks are substantially lower that of MLH1 and MSH2 mutation
carriers. Data from this study show that individuals with LS and an MSH6 mutation have
less overall risk for cancer compared to MLH1 and MSH2 mutation carriers (15). Much
of the data we have regarding LS and EC is extrapolated from CRC registries, which tend
to be dominated by MLH1 and MSH2 mutations. It is not clear if such data can be
applied to MSH6 mutation carriers, who have a distinct cancer risk profile. Thus, we may
be underestimating and under-diagnosing the number of women with EC and LS.
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Lynch Syndrome Associated Tumors (LATs)
In addition to CRC and EC, other Lynch Syndrome associated tumors (LATs)
have been identified that occur in germline mutation carriers at higher rates than that of
the general population. These LATs include ovary, gastric, small intestine, hepatobiliary
tract, urinary tract, brain and skin (17). For women with germline mutations, the lifetime
risks of EC and CRC are 39.4% and 42.7%, respectively. The risk of developing either
EC or CRC is 73.4% (18). Additionally, women with germline mutations are at least
equally as likely to present with a gynecologic cancer as their sentinel cancer diagnosis as
they are CRC (19).
DNA Mismatch Repair (MMR)
DNA replication is a process in which errors occur at a rate of 1 of every 104
nucleotides. DNA polymerase, an enzyme essential to the replication process, has an
innate proofreading ability which improves the fidelity of DNA replication to 1 in 106
(20). In addition to intra-replicative error repair, there also exist other repair systems that
address errors persistent after DNA replication has been completed. The DNA MMR
system identifies and repairs mismatches in nucleotide pairs following DNA replication.
Figure 1 summarizes the overall process for this system. Following an error in
replication, the MSH2/MSH6 heterodimer recognizes and binds to a base-pair mismatch.
MLH1/PMS2 proteins are recruited, which in turn, recruit Exonuclease 1. The
mismatched base-pair is excised and DNA polymerase inserts the appropriate base-pair in
to the sequence (21). Germline mutations in the DNA MMR repair genes, MLH1, MSH2,
MSH6 and PMS2, are the genetic basis for Lynch Syndrome.
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Figure 1. Schematic representation of DNA MMR system.
A. Nucleotide mismatch occurs
B. MSH2/MSH6 heterodimer surveys DNA, recognizes error, and
initiates MMR process
C. MLH1/PMS2 are recruited, DNA polymerase is displaced from
DNA strands, exonuclease is recruited and mismatched pair
is removed
D. DNA polymerase returns and resynthesized DNA with correct
strand
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Molecular Diagnostic Tools In the Evaluation for Lynch Syndrome
Tissue-based Screening Methods: Microsatellite Instability, Immunohistochemistry, and
MLH1 methylation
Tissue-based LS screening assays emerged in the 1990s, providing another
clinical tool in identifying individuals who should proceed with germline testing. DNA
microsatellites consist of multiple, tandem repeats of mono-, di-, and tri- nucleotides;
such repeats are prone to errors during the DNA replication process. Errors in DNA
replication resulting in a change in the number of tandem repeats is termed microsatellite
instability (MSI) (22). The Bethesda Panel is a published set of microsatellite sites
recommended for PCR-based MSI analysis. An earlier panel included BAT-25, BAT-26,
D5S346, D2S123 and D17S250, with subsequent recommendations to add BAT40 and
TGF-βR2 (6). Using the panel of 7 microsatellites, a tumor exhibiting allelic shift in 3 or
more markers is designated as MSI-high (MSI-H), 1-2 markers is MSI-low (MSI-L), and
no allelic shift is microsatellite stable (MSS). Lynch Syndrome associated cancers are
typically MSI-H, while sporadic tumors with no defects in DNA MMR are typically
MSS. MSI-L represents somewhat of a clinical conundrum (23). Nearly all MSI-L
colorectal carcinomas are sporadic. However, a substantial subset of endometrial
carcinomas from women known to have Lynch Syndrome mutations are MSI-L or MSS
(Am J Path 2002 reference emailed to you Sat morning).
In addition to MSI analysis, the development of monoclonal antibodies against
DNA MMR proteins has allowed IHC to become another technique available in
evaluating for LS. Tumors with positive nuclear expression of these proteins typically
have an intact MMR system. Loss of protein expression in tumor cell nuclei with
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preserved stromal cell staining is suggestive of LS. Individuals with mutations in MLH1
will typically have IHC loss of MLH1 and PMS2, while patients with MSH2 mutations
will have IHC loss of MSH2 and MSH6, due to the dominant role of MLH1 and MSH2
in heterodimer formation of the MMR complex. Individuals with germline mutations in
MSH6 or PMS2 typically show only IHC loss of the corresponding MMR protein (24,25).
Approximately 15-20% of all endometrial and colorectal adenocarcinomas have
epigenetic silencing of the MLH1 promoter secondary to methylation (26-28). Between
65-96.9% of endometrial tumors exhibiting MLH1 loss have methylation at the MLH1
promoter region (29-32). By performing this PCR-based assay as part of the LS
evaluation, unnecessary and costly genetic testing can be avoided. Despite the
availability of this assay, it is not universally utilized in published clinical studies (3336). One reason is that PCR-based technology may not be as readily available in all
pathology laboratories, whereas performance of IHC is fairly straightforward, less
expensive, and more universally available.
Performance of MSI and IHC
The utilization of MSI or IHC to aid in the evaluation for LS varies across
different institutions based on resources and departmental standards. A recent study by
Bartley et. al examined the concordance/discordance between MSI and IHC in patients
undergoing tumor testing in the evaluation for LS (37). The majority of tumors evaluated
were colorectal adenocarcinomas (88%), with a smaller fraction of endometrial
adenocarcinomas (7%). They found an overall concordance of MSI and IHC results in
97.8% of tumors.
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The overall sensitivity of MSI and IHC analyses for identifying LS germline
mutations in CRCs is similar, with rates of 83% and 94%, respectively (38). The slightly
decreased sensitivity of MSI is attributed to MSH6 and PMS2 mutations, which more
often tend to be associated with MSS and MSI-L tumors (39,40).
BRAF and Endometrial Cancer
In colorectal cancers, 5-10% of sporadic, MSI-H tumors will be associated with a
mutation in the BRAF gene, a component of the MAPK pathway (41). The prevalence of
this mutation in CRCs has made BRAF analysis a component of standard tumor testing in
evaluation CRCs for LS. In particular, BRAF mutation analysis may be useful in patients
with CRCs with IHC loss of MLH1, when an MLH1 methylation assay is not available.
BRAF mutations are exceedingly rare in EC (30,34,42), so this test has not been
incorporated into the clinicopathologic algorithms for LS evaluation in EC patients.
Pathologic Features Associated with Lynch Syndrome
There are certain pathologic features in EC that have been shown to be associated
with LS tumors. These features include tumors arising from the lower uterine segment
(LUS), tumors with peritumoral lymphocytes, and presence of tumor infiltrating
lymphocytes (43,44). LUS tumors are a relatively rare phenomenon, occurring in only
3.5% of all endometrial adenocarcinomas; however, the prevalence of LS in this subset of
patients is 29% (44). The presence of peritumoral lymphocytes, lymphocytes
surrounding a tumor at scanning power microscopically, has an odds ratio of 2.8 in
predicting PLS tumors (43). Similarly, tumor infiltrating lymphocytes (TILs) are
aggregates of lymphocytes located within the tumor and have an odds ratio of 3.1 in
predicting PLS tumors (43).
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A study investigating the value of young age and the pathologic features of
peritumoral lymphocytes, TILs and heterogeneous tumors (tumors consisting of 2
histologies with each contributing at least 10% to tumor volume) in identifying DNA
MMR defects was performed by Garg et al. Individuals who were either younger than 50
years of age, had any of the aforementioned pathologic findings, or whose primary
physician requested tumor screening were included in their analysis. Their study found
that utilizing age and these features improved detection of tumors that correlated with
DNA MMR defects (45). It should be mentioned here that endometrial carcinomas with
these unique features (young age of diagnosis, heterogeneous histology, LUS anatomic
location, and TILs) can indeed be associated with Lynch Syndrome. But, because
population-based studies are lacking, it is less certain whether the majority of Lynch
Syndrome-associated endometrial carcinomas have these unique features.
National Recommendations of Ideal Screening Strategy for LS
In 2009, the Evaluation of Genomic Applications in Practice and Prevention
(EGAPP) Working group (EWP) published their recommendations regarding LS
screening among CRC patients. They placed less emphasis on using family history as an
initial triage tool, recommending that all patients with CRCs undergo evaluation for LS in
the form of MSI and/or IHC testing and (46). The reasoning behind the removal of
family history resulted from several factors. First, Amsterdam II and Revised Bethesda
criteria, both heavily dependent on utility of family history, have far from optimal
sensitivity or specificity. Next, obtaining an accurate family history often requires a
skilled professional such as a genetic counselor. This requires both time and clinical
resources in addition to patient compliance. Finally, these criteria work less well for
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patients from small families or in scenarios in which the family history of cancer is not
known. Although the working group removed family history as a requirement, it did not
deter the health care team from utilizing this information as part of the full evaluation for
LS.
A recent publication from the Cleveland Clinic evaluated three universal tumor
testing regimens and found the approach that led to the best detection rate and follow up
was universal testing in which the surgeon and genetic counselor both played lead roles
in patient notification and follow-up (47). A national consensus on the ideal method of
screening for LS among EC patients is not available. While the publication of SGO
criteria helped to define the likelihood of identifying a Lynch Syndrome mutation in
women with EC, this group did not provide recommendations on methods of patient
screening.
Germline Testing
The traditional “gold standard” for diagnosing LS is to perform sequencing to
detect a known germline mutation in one of the DNA MMR genes. This involves
sequencing of the coding region of the gene and, in the case of PMS2, the performance of
multiplex ligation-dependent probe amplication (MLPA) to detect mutations in the PMS2
pseudogene. Mutations in MMR genes are not in hot spots, as is the case for KRAS or
BRAF mutations. Sequencing has excellent sensitivity for detecting point mutations and
minor insertions and deletions, but accurate detection of large deletions, insertions or
gene rearrangements is a limitation of conventional sequencing technology (48). It is
unclear whether individuals with molecular diagnostic testing results (IHC loss of MMR
protein, MSI-H) suggestive of LS with negative germline testing are truly negative for
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Lynch Syndrome or if their mutations have genetic features that make identification by
conventional sequencing methods difficult. This is a controversial topic in the field of
Lynch Syndrome research.
Cancer Prevention for Individuals with Lynch Syndrome
After the time of sentinel cancer diagnosis, an individual has a cumulative 1.5-3%
yearly risk of developing a second LAT (49). The identification of LS at the time of
sentinel cancer diagnosis allows for heightened cancer screening in the individual as well
as testing and appropriate screening of first degree relatives (FDRs). Heightened CRC
screening, via colonoscopy every 1-2 years, decreases the incidence of CRC among
individuals with LS by 62% (50). The ideal methods of screening for endometrial and
ovarian cancers are not known, but many experts agree that yearly evaluation of the
endometrial cavity with endometrial biopsy and/or transvaginal ultrasound is a reasonable
approach.
Women with known germline mutations may elect to undergo prophylactic
hysterectomy and/or bilateral salpingo-oopherectomy to reduce their risk of developing
endometrial or ovarian cancer. A study by Schmeler et. al compared gynecologic cancer
outcomes among germline mutation carriers between those who did and did not undergo
prophylactic surgery. Findings showed a 33% incidence of EC among those who were
managed expectantly compared to 0% in the prophylactic surgery group. Incident cases
of ovarian cancer were too small to determine statistical significance (51).
Costs Associated with Screening Strategies
There are ample data supporting effective identification of patients with LS and
prevention of subsequent cancers in both affected individuals and primary tumors in first
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degree relatives (FDRs). The concept of cost analysis to ascertain the benefit of various
health strategies emerged in the 1990s as a tool to assist in determining the best treatment
and prevention strategies both in terms of clinical effectiveness as well as cost
effectiveness.
Four different subtypes of cost analysis exist: cost minimization analysis, cost
effectiveness analysis, cost utility analysis, and cost-benefit analysis. Cost minimization
analysis is perhaps the simplest evaluation, comparing strategies of equal effectiveness to
determine which is the least expensive. Cost effectiveness analysis compares alternative
strategies for a specific condition or disease and evaluates both cost and outcome. Cost
utility analysis incorporates mortality and morbidity into alternative strategies being
compared, utilizing quality adjusted life year (QALY) as its metric of measurement.
Lastly, cost-benefit analysis compares alternative strategies with different effectiveness
and different costs (52). These strategies are often employed utilizing computer-based
algorithms based on large cohorts of hypothetical patients. Assumptions are then placed
into the model based on published literature and individual analysis inclusion criteria.
Regardless of the type of analysis used for a study, there are three key elements at
the foundation of any economic healthcare study. First, define the approaches being
compared, such as standard of care vs. a new strategy for a disease treatment. Second,
the perspective of which we are basing costs relays whether this is from the viewpoint of
the patient, hospital/care provider, or society. Lastly, the outcome(s) being measured
should be clearly defined. This can be either very broad or quite focused in nature
depending on the goals of the study (52).
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In response to the recommendations by the EWG in 2009 that all CRCs should be
offered laboratory evaluation of their tumors, Mvundura et al. investigated the cost
effectiveness of such an initiative and compared it to age-targeted testing (testing all
cases occurring before age 50). The strategies being compared were: 1) IHC testing for
all DNA MMR proteins with genetic sequencing based on IHC results for those with loss
of MSH2, MSH6 or PMS2 and those with loss of MLH1 with negative BRAF testing; 2)
IHC testing for all DNA MMR proteins and IHC directed genetic sequencing for those
with loss of any protein type; 3) MSI testing of all tumors with gene sequencing for all
MSI-H tumors; and, 4) genetic sequencing of all tumors. They utilized a decision model
involving 150,000 hypothetical patients. The costs accounted for in this study were those
associated with identifying LS for each strategy as well as the costs associated with
genetic counseling, genetic testing, surveillance for CRC, and complications of
colonoscopy for both the individual and his/her first-degree relatives. The outcome
measure was both discounted life-years (LY) saved and quality-adjusted life years
(QALY). The authors concluded that the most effective economic strategy was Strategy
1 (53).
Kwon and colleagues initiated a similar study in EC to evaluate the costeffectiveness of several different screening strategies. They used a Markov Monte Carlo
simulation model to perform a cost analysis comparing six different models for detecting
LS in EC. The strategies compared were: 1) those meeting Amsterdam II criteria; 2)
women aged younger than 50 at diagnosis with at least one first degree relative (FDR)
with an LAT; 3) IHC of all women aged younger than 50 at diagnosis with targeted
germline testing based on IHC results; 4) IHC of all women aged younger than 60 at
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diagnosis with targeted germline testing; 5) IHC for any woman with at least one FDR
had an LAT; 6) IHC of all EC cases. The incremental cost effectiveness ratio (ICER)
was the metric used to compare these groups; it is “the additional cost of a specific
strategy divided by its health benefit compared with an alternate strategy”(33). In
general, an ICER of $50,000 per QALY or less has been arbitrarily accepted as a costeffective strategy (54). They found that IHC triage of women with EC who had 1 FDR
with an LAT was the most favorable screening strategy with an ICER of $9,126 per year
of life gained (33).
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Hypothesis and Specific Aims
The absence of population-based evaluations of SGO 5-10% clinical criteria in
the endometrial carcinoma literature has prompted us to investigate its performance in an
unselected cohort of EC patients. These criteria parallel the Bethesda Guidelines, which
were derived from data from colorectal cancer registries. Given the fact that these
guidelines are extrapolated from CRC patient data, we hypothesize that SGO 5-10%
criteria (which will be referred to as SGO Criteria from this point on) will fail to identify
a majority of LS patients in the EC population.
Specific Aim 1. Evaluate the performance of SGO Criteria in detecting
individuals at elevated risk for LS in endometrial cancer.
A1) Calculate the sensitivity and specificity of SGO Criteria in
identifying probable Lynch Syndrome (PLS) EC cases in a
convenience sample in which molecular testing has already been
performed.
A2) Determine the number of individuals who meet MDACC institutional
screening criteria who actually receive referrals for genetic
counseling.
B) Calculate the sensitivity and specificity of SGO Criteria in an
unselected, sequential cohort of EC cases in identifying PLS cases.
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Specific Aim 2. Determine if clinicopathologic features distinguish
sporadic EC from PLS EC.
A) Determine if historical risk factors of LS such as low BMI, young age
at diagnosis and strong family history are significantly different
between sporadic EC and PLS EC cases.
B) Compare clinicopathologic characteristics between sporadic and PLS
EC cases to determine if alternative clinical screening criteria exist.
C) Determine the utility of MLH1 methylation analysis in the evaluation
of endometrial carcinomas with IHC loss of MLH1.
Specific Aim 3. Perform a simplified cost-effectiveness analysis comparing
direct costs of utilizing a clinical history-based model, SGO Criteria, to a
universal tumor testing model (immunohistochemistry and MLH1 methylation
analysis when indicated).
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Methods
Institutional Approval
This study received Institutional Review Board Approval by the University of
Texas, MD Anderson Cancer Center IRB (PA12-0131).
Patient Population
Convenience Cohort
350 EC patients were identified who had previously undergone IHC
analysis for DNA MMR protein expression at MD Anderson Cancer Center, with
complete clinicopathologic information available for 337. The majority in this
cohort, 149 (44.2%), were from a protocol in which EC cases were selected based
solely on matched frozen tumor tissue availability (55). Fifty-five EC cases came
from a study evaluating the prevalence of LS among women diagnosed with EC
prior to age 50, a risk factor known to increase an individual’s risk for having LS
(56). An additional 52 cases were derived from a study that evaluated women
with synchronous endometrial and ovarian cancers, an indicator in Revised
Bethesda guidelines for tissue testing for LS (57). Fifty-one cases were obtained
from a study evaluating the concordance between MSI testing and IHC in LATs,
with most of these patients recruited based on young age and family history of
LATs (37). An additional 17 patients were obtained from a study investigating
the association of LS and LUS tumors (44). The remaining 13 EC patients were
known to have LS germline mutations.
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Unselected, Sequential Cohort
Using a Department of Pathology database, we identified patients
diagnosed with endometrial cancer between 2004-2011 who had undergone
surgery at the University of Texas, MD Anderson Cancer Center. EC cases were
included if the woman was 18 years of age or greater, surgery was performed at
MD Anderson Cancer Center, and sufficient tissue was available for molecular
analysis. All histotypes of endometrial carcinoma were included. Selection was
not based on historical risk factors for LS such as young age at diagnosis or
family history.
Genetic Counseling Referral Cohort
To assess the genetic counseling referral process, we retrospectively
reviewed clinical and pathologic data for endometrial cancer cases at MD
Anderson Cancer Center between 2007-2010. Patient clinical history was
obtained from the electronic medical record. At the time of this analysis,
institutional referral criteria were as follows: 1) any patient with a history of CRC;
2) any patient with an FDR with CRC or EC; 3) any patient with a relative of any
degree with EC or CRC diagnosed before age 50; or 4) any patient with relatives
who have a known LS germline mutation. Patients were classified as either
“meets criteria for genetic counseling referral” or “genetic counseling referral not
warranted.” Then, genetic counseling referrals were charted for each patient in
the “meets criteria” category.
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Data Collection
Clinical data were extracted from the electronic medical record (EMR). Data
recorded included race/ethnicity, age at EC diagnosis, age of menarche and menopause,
gravidity/parity, history of cancer, history of any hormone replacement therapy, BMI
(kg/m2), past medical history of diabetes/hypertension/thyroid disease, family history of
cancer, and total number of first-degree relatives (FDRs).
Tumor characteristics were derived from pathology reports generated by 6
gynecologic pathologists. Recorded pathologic data included: tumor histology, tumor
location (corpus/LUS), tumor grade, surgical stage, largest tumor dimension (cm), depth
of invasion, and presence of lymph-vascular space invasion (LVSI).
Immunohistochemistry
Immunohistochemical analyses for the nuclear protein expression of MLH1,
MSH2, MSH6, and PMS2 were performed on sections from formalin-fixed, paraffinembedded endometrial carcinomas. IHC was performed using standard techniques for
MLH1 (G168-15, 1:25; BD Biosciences Pharmingen), MSH2 (FE11, 1:100;
Calbiochem), MSH6 (44, 1:300; BD Biosciences Pharmingen), and PMS2 (Alb-4, 1:125;
BD Biosciences Pharmingen (37,57). A tumor exhibiting nuclear loss of protein
expression by light microscopic examination was designated as negative for that MMR
protein. The presence of nuclear staining in surrounding stromal and normal tissues
served as internal positive controls (Figure 2).
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Figure 2A and 2B. Example of IHC retention (A) and loss (B) of
MMR protein expression
expression. Non-nuclear
nuclear staining of both tumor cell
nuclei and stromal cell nuclei in (A) and retention of stromal cell
nuclear staining in (B) without presence of tumor staining.
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MLH1 Methylation
For cases in which there was IHC loss of MLH1 protein expression, PCR-based
MLH1 promoter methylation analysis was performed. DNA was isolated from formalinfixed, paraffin-embedded tissue sections that were microdissected with a scalpel blade to
provide relatively pure tumor samples for analysis. Isolated DNA was treated with
bisulfite to convert methylated cytosine to uracil. The treated DNA was then amplified
using fluorescently labeled PCR primers that were specific for methylated (M) or the
unmethylated (U) versions of MLH1 (MLH1-M forward, 5_-gatagcgatttttaacgc-3_ and
MLH1-M reverse, 5_-tctataaatactaaatctcttcg-3_; MLH1-U forward, 5_agagtggatagtgatttttaatgt-3_ and MLH1-U reverse, 5_-actctataaattactaaatctcttca-3_).
Amplified PCR products were then detected using capillary electrophoresis and
GeneScan software. Chromatograms for tumor were compared to those generated for the
RKO colon carcinoma cell line (positive control known to have loss of MLH1 protein
due to MLH1 promoter methylation) and the leukemia cell line K562 (negative control
with no MLH1 methylation) (Figure 3) (57).
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Figure 3. For cases with IHC loss of MLH1, PCR-based MLH1 promoter
methylation analysis was performed. Rows 1 and 2 are negative and positive
controls, respectively. Row 3 and 4 show normal and tumor tissue from the same
patient, respectively. The absence of a second peak in the normal tissue and presence
of a second peak in the tumor indicates methylation of the MLH1 promoter in the
tumor.
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Definition of Probable Lynch Syndrome (PLS) and Sporadic EC Tumors
Tumors with intact IHC nuclear staining for all 4 DNA MMR proteins and those
with MLH1 loss and MLH1 promoter methylation were designated sporadic tumors.
Tumors with absent nuclear staining for MSH2, MSH6 or PMS2 were designated as PLS.
Tumors exhibiting MLH1 loss with absence of MLH1 promoter methylation were also
designated as PLS.
Statistical Analysis
Statistical analyses were conducted using SAS software, version 9.2 (SAS, Inc.
Cary, NC). Clinical and pathological criteria were compared across a variety of groups.
Fisher’s, chi-squared, Mann-Whitney, or t-test were conducted to test association across
groups depending on the distribution of the data. CART analysis was performed to
attempt to select a set of variables that would predict Lynch Syndrome, but none of the
models were good fits. Sensitivity and specificity were also calculated for SGO Criteria
in its ability to predict PLS EC tumors in both the convenience sample cohort and
unselected, sequential cohort.
Cost-effectiveness Analysis
The cohort of 412 unselected, sequential EC cases was used to perform a
simplified cost-effectiveness analysis. The direct costs of utilizing SGO Criteria were
compared to universal tumor testing (IHC and MLH1 methylation analysis when
indicated) of all EC tumors. Effectiveness was expressed in two ways: 1.) the number of
women with EC in which PLS was identified, and 2.) the total number of women with EC
in which PLS was identified as well as identification of LS in their FDRs. Both technical
and professional costs were collected for genetic counseling visits, IHC for the 4 DNA

27

MMR proteins, MLH1 promoter methylation assay for tumors with IHC loss of MLH1,
and single gene germline testing. The cost of single site genetic testing was used for
identification of mutations in FDRs.
Cost analyses were performed using both institutional costs and Medicare
reimbursement fees. MDACC institutional cost data were provided by the Department of
Clinical Revenue and Reimbursement for specific procedure codes (CPT codes) derived
from a review of billing records and CPT codes. Table 3 shows a list of items and costs
included in these analyses. Medicare reimbursement figures were obtained from the
Physician Fee Schedule and Laboratory Fee Schedule
(http://www.cms.gov/Medicare/Medicare-Fee-for-ServicePayment/PhysicianFeeSched/index.html). All cost amounts are shown in 2012 US
dollars.
In the SGO Criteria model, the original 412 EC cases were stratified according to
whether or not they fulfilled SGO 5-10% criteria and only those tumors meeting criteria
underwent further work-up with IHC for DNA MMR proteins, MLH1 methylation when
indicated, and genetic counseling. In the universal tumor testing model, all 412 EC cases
underwent IHC following hysterectomy, and PLS patients underwent genetic counseling
and germline testing.
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Table 3. Unit costs included in screening strategies (expressed in 2012 US dollars)1
MDACC
institutional
costs

Medicare
reimbursement
amounts

Initial genetic counseling
consultation (1 hr) a

$264

$210

Follow-up genetic counseling
visits (30 min)b

$132

$104

IHC for MLH1, MLH2,
MSH6, and PMS2 c

$349

$422

MLH1 promoter methylation
assay for tumor with IHC
loss of MHL1 d

$316

$125

Single gene germ-line
testing2

$1300

$1300

Single site testing3,4

$475

$475

1

Includes technical and professional components
Cost of germline testing was obtained from Myriad ABN worksheet
3
Cost of single site testing was obtained from Myriad ABN worksheet
4
Single site testing intended for first degree relatives of pts with endometrial cancer who
were identified as having Lynch Syndrome based upon positive germline test results
a
MDACC costs derived from CPT code 96040 in 2010 billing statements and converted to
2012 US dollars. CPT 99215 and CPT 99213 were used to determine Medicare
reimbursement amounts from the 2012 Fee Schedule.
b
Costs adapted from CPT code 99214.
c
CPT code 88342 used for each individual IHC DNA MMR protein
d
CPT codes 83900, 83909, 83912 from 2012.
2
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The following assumptions were made for the cost effectiveness analysis: 1)
women with PLS would all be willing to undergo genetic counseling and recommended
germline testing; 2) women identified as PLS by SGO Criteria had an average of 5.3 first
degree relatives and women identified as PLS by universal tumor testing had an average
of 5.5 first degree relatives (these numbers were extracted from the electronic medical
record); 3) all FDRs recommended to undergo screening and testing would be compliant.
Finally, to evaluate the impact on the incremental cost per additional case of
Lynch Syndrome identified, we varied our assumptions regarding the proportion of FDRs
who would have positive germline tests (e.g. single-site test based upon initial germ line
mutation found in women with PLS) from 25% to 75%. These estimates of 25%, 50%,
and 75% are based on the variable rate at which immunohistochemistry is found to
predict germline mutations (48,58). The incremental cost-effectiveness ratio (ICER) is
an estimate of the cost per unit of effectiveness of different screening strategies. We
varied the percentages of FDRs we assumed would test positive, between 25%-75%, to
evaluate how cost-effectiveness ratios would differ based on these assumptions within a
given strategy. The ICER is calculated as the difference in costs between alternative
screening strategies divided by the difference in effectiveness between screening
strategies (Figure 4).
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SGO Criteria Costs – Baseline Costs
Incremental Cost Effectiveness Ratio (ICER)SGO =
SGO Effectiveness – Baseline Effectiveness

UTT Costs – SGO Criteria Costs
Incremental Cost Effectiveness Ratio (ICER)UTT=
UTT Effectiveness – SGO Effectiveness

Figure 4. Equations used to derive the ICER for SGO (comparing SGO to no
intervention) and ICER for Universal tumor testing (UTT) (comparing UTT to SGO
criteria costs). Effectiveness is the number of PLS cases identified.
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Results
Aim 1A1. Performance of SGO Criteria in a Convenience Sample of EC Cases
Three-hundred-and-fifty cases of endometrial cancer were identified that had
previously undergone immunohistochemical analysis for DNA MMR protein expression at
MD Anderson Cancer Center, and complete clinicopathologic information was available for
337 (Figure 5). There was an average of 5.3 FDR per PLS case identified.
In this cohort, 56/337 (16.6%) were PLS EC tumors. IHC loss of MLH1/PMS2 with
unmethylated MLH1 occurred in 14/56 (25%), loss of MSH2/MSH6 in 24/56 (42.8%), loss
of MSH6 only in 11/56 (19.6%) and loss of PMS2 only in 7/56 (12.5%). The median BMI of
all PLS cases was 32.0, and median age at diagnosis was 49.
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350 EC Cases
Insufficient clinicopathologic data
N = 13
337 EC Cases

IHC
(MLH1, MSH2, MSH6, PMS2)

Intact Nuclear Expression
Sporadic EC
N = 241

Loss of Nuclear
Expression

MSH2, MSH6, PMS2
PLS - EC
N = 42

MLH1

Methylated MLH1
Promoter
Sporadic EC
N = 40

Unmethylated
MLH1 Promoter
PLS EC
N = 14

Figure 5. Immunohistochemical and MLH1 methylation results for a convenience sample of
350 Endometrial Cancer Cases.
EC: endometrial cancer
IHC: immunohistochemistry
PLS: probable Lynch Syndrome
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Sensitivity and specificity of SGO Criteria were 76.8% and 44.4%, respectively. For
EC cases meeting SGO Criteria, mean age at diagnosis was 48 years, mean BMI was 33.6,
17.7% had a family history of EC and 46.9% had a family history of CRC. Tumor location
in the lower uterine segment (LUS) was in 25.6% of these cases. In the 43/56 PLS cases
meeting SGO Criteria, IHC loss of MLH1/PMS2 occurred in 11, MSH2/MSH6 in 21, MSH6
only in 7, and PMS2 only in 4.
Of the 13 (23.2%) patients not captured by clinical criteria, mean age was 68 years,
mean BMI 34.4, no cases had a family history of CRC and one patient had a first-degree
relative with a gynecologic cancer of unknown origin. EC cases missed when employing
SGO screening criteria were associated with IHC loss of MLH1/PMS2 in 3, MSH2/MSH6 in
3, MSH6 only in 4, and PMS2 only in 3 instances. Tumor arising from the LUS occurred in
33.3% of these cases. If LUS tumors were made a component of SGO Criteria, sensitivity
and specificity in this cohort become 85.7% and 40.2%, respectively.
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AIM 1A2. Number of individuals meeting MDACC Criteria Referred for Genetic Counseling
Between 2007-2010, 1064 endometrial cancer patients new to MDACC were seen in
the gynecology oncology clinic. Of these, 156 (14.7%) met institutional guidelines for
referral to a genetic counselor to assess risk for LS. Forty-nine of these patients (30.2%)
received a recommendation to see a genetic counselor (Figure 5). Of the 107 EC patients
meeting criteria but not referred to genetic counseling, a large number had compelling
personal or family histories of cancer. One EC patient had a prior history of CRC, 57 had a
FDR with CRC (5 diagnosed at less than age 50), and 29 had a FDR with EC (3 diagnosed at
less than age 50). Six EC patients had a FDR history significant for both EC and CRC.
Additionally, only 12/30 EC patients who had a second degree relative with an LAT
diagnosed before age 50 received a referral.
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Endometrial Cancer Cases
(2007-2010)
N = 1064

Meets MD Anderson
Institutional Criteria
N = 156

Referred to Genetic
Counselor
N = 49

Does not MD Anderson
Institutional Criteria
N = 908

No referral to Genetic
Counselor
N = 107

Figure 6. Referral experience of endometrial cancer patients who meet MDACC
Gynecologic Oncology Center Genetic Counseling Criteria for Lynch Syndrome evaluation
from 2007-2010.
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Aim 1B. Performance of SGO Criteria in an unselected cohort of EC cases
From the results of the convenience sample study in Aim 1A1, it was noted that a
substantial subset of PLS patients were older than age 50 and/or did not have compelling
family histories of CRC or EC. Therefore, we hypothesized that LS screening in a
population-based fashion would identify patients who would otherwise not be identified
when screening is based on historical risk factors. Four hundred twelve consecutive,
unselected EC cases met inclusion criteria and underwent molecular testing (Figure 7). There
was one case in which immunohistochemistry and three cases in which MLH1 methylation
were unsuccessful. Of the 411 cases with complete IHC results, 118 had loss of at least one
MMR protein (90 MLH1/PMS2, 12 MSH2/MSH6, 9 MSH6 and 7 PMS2). Of those with loss
of MLH1/PMS2, 72/90 (80%) had methylation of the MLH1 promoter (Figure 7). The total
number of PLS EC cases in our series was 43 (10.5%). There was an average of 5.5 FDRs
per PLS EC case identified in this cohort.
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412 EC Cases
IHC unsuccessful
N=1

Immunohistochemistry
MLH1, MSH2, MSH2, PMS2
N = 411

Intact nuclear
expression for
all proteins
Sporadic EC
N = 293

Loss of
expression of
at least one
protein

Loss of MLH1
N = 90

Loss of MSH2,
MSH6, PMS2
PLS EC
N = 28

MLH1 promoter
methylation
assay
Assay unsuccessful (N =3)

Methylated Promoter
Sporadic EC
N = 72

Unmethylated
Promoter
PLS EC
N = 15

Figure 7. IHC and MLH1 methylation results of the unselected, sequential cohort of EC
cases.
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Demographic and pathologic information for this cohort is summarized in Table 4.
The median age at diagnosis was 60.5 with a range of 18-92. Most patients were of white
ethnicity, older than age 50 years, obese (BMI ≥ 30 kg/m2), and had unremarkable family
histories for EC or CRC. The median tumor size was 4.3 cm. Most tumors were
endometrioid histology, low grade, early stage, and located in the corpus.
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Table 4. Demographic and pathologic data for
the cohort of unselected, sequential EC cases.
Characteristic
Race
White
Non-White
Age (years)
< 50
≥ 50
History of Any Cancer
Yes
No
Synchronous Tumor (any type)
Yes
No
BMI (kg/m2)
< 30
≥ 30
History of Diabetes
Yes
No
Family History of EC
Yes
No
Family History of CRC
Yes
No
Histology
Endometrioid
Non-endometrioid
Grade
1&2
3
Stage
I & II
III & IV
Tumor Location
Corpus
Lower Uterine Segment

Number (%)
270 (66.2)
138 (33.8)
62 (15.2)
346 (84.8)
53 (13.0)
355 (87.0)
27 (6.6)
381 (93.4)
138 (33.9)
269 (66.1)
98 (24.0)
310 (76.0)
39 (9.8)
360 (90.2)
66 (16.5)
335 (83.5)
336 (82.4)
72 (17.6)
299 (73.3)
109 (26.7)
326 (79.9)
82 (20.1)
395 (96.8)
13 (3.2)
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The sensitivity and specificity of SGO Criteria and its associated 95% confidence
intervals are 34.1% (20.5, 49.9) and 77.6 % (72.9,81.8), respectively. The sensitivity of SGO
Criteria by type of IHC loss is presented in Table 5. SGO Criteria perform best in patients
with tumors exhibiting IHC loss of MLH1/PMS2 or MSH2/MSH6 and perform poorly in
tumors with IHC loss of only MSH6 or PMS2.
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Table 5. Sensitivity and specificity of SGO Criteria in identifying PLS EC cases.

Probable Lynch Syndrome
(N = 43)

Sensitivity
(95% CI)
32.6
(19.1 – 48.5)

Specificity
(95% CI)
77.2
(72.7 – 81.6)

MLH1/PMS2
(N = 15)

40.0
(16.3 – 67.7)

---

MSH2/MSH6
(N = 12)

42.7
(15.2 – 72.3)

---

MSH6
(N = 9)

22.2
(3.0 – 60.0)

---

PMS2
(N = 7)

14.3
(0.3 – 57.9)

---
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Ninety-seven of 408 (23.8%) of all EC cases fulfilled SGO Criteria. Of these, 14/97
(14.4%) were PLS EC tumors based on tissue testing and 83/97 (85.6%) that would be
characterized as sporadic based on tissue testing. This also results in 29/43 (67.4%) PLS
tumors that did not meet criteria that would go undetected in a clinical screening criteria
based referral system.
For the 43 patients identified by tissue testing as PLS, the patterns of IHC loss
between those that do and do not meet SGO Criteria were examined (Figure 7). Tumors with
IHC loss of MLH1 and MSH2 were the predominant types of PLS tumors among those that
fulfill SGO Criteria (11/14). Among those failing to meet criteria (n=29), there is a fairly
equal distribution of types of IHC protein loss. IHC loss of MLH1/PMS2 occurred in 9,
MSH2/MSH6 in 7, MSH6 only in 7, and PMS2 only in 6.
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A

B

Figure 8. Type of IHC protein loss for EC cases do (A) and do not (B) meet SGO Criteria.
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Select clinical and pathologic characteristics between those that do and do not meet
clinical criteria were further investigated (Table 6). Those patients meeting SGO Criteria had
a younger age at diagnosis, stronger family history of EC and CRC, and a higher frequency
of tumors arising from the lower segment than those who do not meet criteria. Regardless of
whether or not criteria are met, the majority of PLS EC cases do not have a family history of
EC or CRC.
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Table 6. Features of EC patients who do and do not meet SGO Criteria.
Total PLS
N = 43
Median age at diagnosis
Average BMI (kg/m2)
Family History of EC1
Family History of CRC2
LUS Tumor3

Meets SGO Criteria
N = 14
48.5
32.0
2/14 (14.3%)
4/14 (28.6%)
3/14 (21.4%)

Does Not Meet SGO
Criteria
N = 29
63.0
33.0
2/29 (6.9%)
4/29 (13.8%)
2/29 (6.9%)

1

EC, endometrial cancer
CRC, colorectal cancer
3
LUS, tumor arising from lower uterine segment
2
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Specific Aim 2A. Evaluation of Historical LS risk factors
Young age at cancer diagnosis is one of two fundamental characteristics present in
published clinical screening criteria for LS. Our data show that 62/408 (15.2%) of all EC
occurred in patients younger than 50 years of age. Of these 62 cases, 10/62 (16.1%) were
PLS tumors, and 10/43 (23.2%) of all PLS tumors occurred in this age category. Thus, 75%
of PLS cases in this cohort occur at older ages. Figure 9 shows the distribution of EC cases
by age. The median age at diagnosis is 61 years for both sporadic EC and PLS EC groups.
The age range for patients with sporadic tumors is wider (18-92) than for PLS (42-87). PLS
cases did not occur at less than age 40, whereas sporadic EC occurred as young as 18 years.
After age 40, the proportion of individuals with PLS or sporadic EC at any age is similar.
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All EC
Cases
Sporadic
EC
PLS
EC

Age (Years)
Figure 9. Distribution by age of EC cases for all EC tumors, sporadic tumors, and
PLS tumors.
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The other fundamental characteristic of published screening criteria is a strong family
history of EC or CRC. Less than 30% of EC patients in this cohort had a family history of
either EC or CRC. Table 7 shows the family histories of EC, CRC and either EC or CRC for
the sporadic and PLS EC groups. Family history of these cancers does not distinguish
sporadic from PLS.
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Table 7. Family history of EC, CRC, and EC or CRC in sporadic and PLS EC cases
in the unselected, sequential cohort.
Family History
EC
CRC
EC or CRC

Sporadic EC
N (%)
35 (9.8)
58 (16.2)
87 (24.2)

PLS EC
N (%)
4 (9.8)
8 (19.0)
12 (28.6)

p-value
> 0.99
0.63
0.54
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Specific Aim 2B. Comparison of clinicopathologic features in PLS and Sporadic EC to
determine if alternative screening criteria exist
Clinicopathologic characteristics were compared between the sporadic and PLS
patients in our sequential, unselected cohort (Table 8). With the exception of tumors arising
from the lower uterine segment (LUS), there was no statistically significant difference
identified between these two groups. Although not statistically significant, there was a trend
toward younger age at diagnosis (23.3%), lower BMI (39.5%), personal history of
hypertension (58.1%) and smaller tumor (3.6 cm) among the PLS EC cases.
From the complete list of all clinicopathologic data collected, a Classification and
Regression Tree (CART) analysis was performed to determine if more ideal screening
criteria could be generated that could effectively delineate sporadic from PLS EC tumors.
This analysis yielded no superior criteria.
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Table 8. Comparison of clinical and pathologic features between sporadic and PLS EC
cases.
Clinical Features
Age (years)
< 50
≥ 50
BMI (kg/m2)
< 30
≥ 30
History of Diabetes
Yes
No
History of Hypertension
Yes
No
Pathologic Features
Histology
Endometrioid
Non-endometrioid
Stage
I & II
III & IV
Grade
1&2
3
Depth of myometrial invasion
< 50%
≥ 50%
Tumor Location
Corpus
Lower uterine segment
Largest tumor dimension (cm)
Mean
Median

Sporadic EC
N (%)

PLS EC
N (%)

p -value

52 (14.2)
313 (85.8)

10 (23.3)
33 (76.7)

0.12

121 (33.2)
243 (66.8)

17 (39.5)
26 (60.5)

0.41

89 (24.4)
276 (75.6)

9 (20.9)
34 (79.1)

0.62

201 (55.1)
164 (44.9)
Sporadic EC
N (%)

18 (41.9)
25 (58.1)
PLS EC
N (%)

0.10

299 (81.9)
66 (18.1)

37 (86.0)
6 (14.0)

0.67

289 (79.2)
76 (20.8)

37 (86.0)
6 (14.0)

0.42

267 (73.2)
98 (26.8)

32 (74.4)
11 (25.6)

0.86

257 (70.4)
108 (29.6)

32 (74.4)
11 (25.6)

0.85

357 (97.8)
8 (2.2)

38 (88.4)
5 (11.6)

0.007

3.6
3.5

0.13

4.3
4

p -value
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Next, a receiver-operator curve (ROC) was generated in which age was varied within
the SGO Criteria by 1-year intervals (Figure 10). Ideally, the area under the curve is 0.8 or
greater. Varying age does not improve the sensitivity and specificity profiles of SGO
Criteria. Increases in sensitivity come at the cost of decreases in specificity.
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1

Sensitivity

.8

.6

.4

.2

0
0

.2

.4
.6
1 - Specificity

.8

1

Figure 10. Receiver-operator curve (ROC) depicting SGO Criteria with age criteria being
varied in 1–year intervals.
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Finally, clinicopathologic variables for the different types of PLS were compared
(Table 9). There is a trend toward younger median age at diagnosis between those exhibiting
MSH2/MSH6 loss and PMS2 loss only; however, the age range is fairly similar across all
types of MMR deficiency types. There were more individuals with a BMI (kg/m2) < 30 and
no family history of EC in these two groups as well. However, overall, there were no
clinicopathologic variables that distinguished any of these groups.
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Table 9. Comparison of clinicopathologic characteristics by MMR deficiency type.
MLH1/PMS2
No methylation
N = 15

MSH2/MSH6
N = 12

MSH6
N=9

PMS2
N=7

p-value

62

56

62

56

0.50

(Range)

(43-79)

(42-71)

(50-76)

(45-87)

---

BMI < 30

8 (53%)

10 (83.3%)

8 (88.9%)

2 (28.6%)

0.30

FH EC1

3 (21.4%)

0

1 (12.5%)

0

0.31

FH CRC2

3 (20%)

3 (25%)

1 (12.5%)

1 (14.3%)

0.95

LUS3 Tumor

1 (6.7%)

1 (8.3%)

0

3 (42.9%)

0.05

Endometrioid
Histology

13 (86.7%)

9 (75%)

8 (88.9%)

7 (100%)

0.62

Stage I & II

13 (86.7%)

8 (66.7%)

9 (100%)

7 (100%)

0.14

Meets SGO
Criteria

6 (40.0%)

5 (41.7%)

2 (22.2%)

1 (14.3%)

0.62

Median age
at diagnosis

1

EC, endometrial cancer
CRC, colorectal cancer
3
LUS, tumor arising from lower uterine segment
2
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Specific Aim 2C. Utility of MLH1 Methylation Analysis among EC with MLH1 IHC loss
Most EC with MLH1 IHC loss are sporadic secondary to MLH1 methylation rather
than familial due to MLH1 mutation. We investigated whether any clinical or pathological
features can reliably distinguish the MLH1 IHC negative (sporadic) and MLH1 IHC negative
(PLS) endometrial cancer patients. Utilizing the convenience sample of 337 EC cases, IHC
loss of MLH1 nuclear expression was detected in 54/337 (16%) of endometrial tumors. Of
these, 40/54 (74.1%) endometrial tumors demonstrated MLH1 promoter methylation and
were designated as sporadic endometrial carcinomas. The remaining 14/54 (25.9%) lacked
MLH1 methylation and were designated as PLS. The proportion of MLH1 methylated
tumors is comparable to that seen in several other studies consisting of unselected
endometrial cancer patients with a range of 65-96.9% (Figure 11) (29-32).
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350 EC Cases
13 cases removed due to insufficient clinical
or pathologic data

337 EC Cases
Immunohistochemistry for MLH1

Intact MLH1
Nuclear Expression
N = 283

Loss of MLH1
Nuclear Expression
N = 54

Methylated MLH1
Promoter
Sporadic EC
N = 40

Unmethylated MLH1
Promoter
Probable Lynch Syndrome
N = 14

Figure 11. Results of IHC for MLH1 and MLH1 methylation in convenience sample
cohort of EC cases.
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Clinical and pathologic characteristics for the endometrial cancer patients with and
without MLH1 promoter methylation are shown in Table 10. There was no statistical
difference between median age of diagnosis, median body mass index (BMI), or family
history of CRC or EC between the MLH1 methylated and unmethylated promoter groups. A
personal history of diabetes was statistically more common in the unmethylated group.
Investigation of tumor-specific characteristics revealed no statistically significant
differences between the two groups with respect to histology, FIGO stage, endometrioid
grade, lymphatic/vascular space invasion, tumor location, or tumor size (Table 10). Depth of
myometrial invasion was the only pathologic characteristic that was statistically different
between the two groups. Deep myometrial invasion was seen in 37.5% of MLH1 methylated
tumors, whereas 71.4% of the MLH1 unmethylated tumors had myometrial invasion greater
than or equal to 50% myometrial thickness. In this cohort, 25/54 of the patients had
endometrial carcinomas with depth of myometrial invasion greater than or equal to 50% total
myometrial thickness making this a criterion of low specificity.
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Table 10. Patient and tumor characteristics for EC in the convenience sample cohort with
IHC loss of MLH1, stratified by presence or absence of MLH1 promoter methylation.
Methylated MLH1
n (%)

Unmethylated MLH1
n (%)

P - value

Patient Characteristics
Age
Median age at diagnosis
57
52
0.4295
Age range
31-92
42-79
32.9
30.9
> 0.999
Median Body Mass Index
13 (33.3)
5 (35.7)
<30
26 (66.7)
9(64.3)
≥ 30
1
4 (10.5)
3 (21.4)
0.370
Family History of EC
7 (18.4)
3 (21.4)
0.999
Family History of CRC2
4 (10)
6 (42.9)
0.013
Diabetes
23 (57.5)
6 (42.9)
0.371
Hypertension
Tumor Characteristics
Histology
Endometrioid
35 (87.5)
11(78.6)
0.413
Non-Endometrioid
5 (12.5)
3(21.4)
FIGO Stage3
I & II
27 (67.5)
11 (78.6)
0.515
III & IV
13 (32.5)
3 (21.4)
Endometrioid Tumor Grade
1 or 2
9 (81.8)
26 (74.3)
3
2 (18.1)
9 (25.7)
> 0.999
Median depth of myometrial
invasion (mm)4
9.0
9.5
0.487
< 50% myometrial invasion
25 (62.5)
4 (28.5)
0.035
≥ 50% myometrial invasion
15 (37.5)
10 (71.4)
24 (60.0)
8 (57.1)
> 0.999
Lymphatic/vascular space
invasion
Tumor location
Corpus
37 (92.5)
11 (78.6)
0.173
Lower uterine segment
3 (7.5)
3 (21.4)
Tumor Size
< 4 cm
21 (52.5)
8 (57.1)
> 0.999
≥ 4 cm
19 (47.5)
6 (42.9)
1
EC, endometrial cancer
2
CRC, colorectal cancer
3
FIGO stage I and II denote endometrial carcinomas confined to the uterus. FIGO stages III
and IV represent extra-uterine spread of tumor.
4
Depth of myometrial invasion ≥ 50% total myometrial thickness is associated with increased
risk of lymph node metastasis.
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The sensitivity and specificity of various clinical screening criteria and selected
patient characteristics are presented in Table 11. Young age of EC diagnosis was included
here, as this is a common feature included in many different clinical screening criteria for LS.
BMI less than 30 was also included, because it has been previously reported that endometrial
cancer patients with LS have a lower BMI than patients with sporadic endometrial cancer
(56). Single factors such as young age, BMI less than 30, family history of colorectal cancer,
and family history of EC showed poor overall sensitivity and specificity in ability to predict
MLH1 methylation status accurately. The SGO criteria had a moderate sensitivity (71.4%)
and specificity (69.2%). Amsterdam II criteria had a high specificity, 94.9%, at the expense
of sensitivity, only 14.3%. When the statistically significant factors from Table 10, deep
myometrial invasion and patient history of diabetes, were added to SGO 5-10% criteria,
sensitivity increased to 100%, but specificity was low at 35.9%. Overall, SGO 5-10% criteria
had the best sensitivity and specificity profile of the screening criteria evaluated in this cohort
of EC cases.
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Table 11. Sensitivity and specificity of selected clinical characteristics and
screening criteria in predicting presence or absence of MLH1 methylation
in endometrial carcinomas with MLH1 loss by immunohistochemistry

Age < 50
Body mass index < 30
History of diabetes
Myometrial invasion > 50%
Family history colorectal cancer
Family history endometrial
cancer
Amsterdam II Criteria
SGO Criteria
SGO Criteria or ≥ 50%
myometrial invasion or diabetes

Sensitivity
50.0
33.3
42.8
71.4
21.4
21.4

Specificity
77.5
35.7
90.0
62.5
81.6
89.5

14.3
71.4
100

94.9
69.2
35.9
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Since SGO Criteria performed the best in this cohort, we sought to further examine
clinicopathologic features of the 4 EC cases not captured by the criteria. Table 12 presents
patient clinical and pathologic characteristics of the 4 EC cases lacking MLH1 promoter
methylation (PLS) that were not captured by SGO criteria (in other words, 4 patients
designated as sporadic endometrial cancer rather than PLS endometrial cancer). In each case,
patients are older than age 50 years, have a body mass index greater than 30, and there is no
family history of CRC. One patient has an LUS tumor, and all but one of the patients had
deep myometrial invasion.
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Case

Age at EC
Diagnosis1

BMI

DM2

1

61

51.8

No

2
3

64
71

30.9
38

No
Yes

4

79

31

Yes

Family
History of
EC

Cousin
age > 50
No
Mother
unknown
gyn cancer
age > 50
No

Family
History
of
CRC3

Meets
Amsterdam
II Criteria

Tumor
Location
(Corpus
or LUS4)

FIGO
Stage

Tumor
Grade

Tumor
Size (cm)

Histology5

Depth of
Uterine
Wall
Invasion

No

No

Corpus

II

1

13

E

> 50%

No
No

No
No

LUS
Corpus

II
IA

1
2

3
5.5

C
M

> 50%
< 50%

No

No

Corpus

IIIC2

2

1.9

E

> 50%

Table 12. Characteristics of EC cases with immunohistochemical loss of MLH1 and absence of MLH1 methylation (PLS) that were
incorrectly designated as sporadic by SGO criteria
1

EC, endometrial cancer
DM, diabetes mellitus
3
CRC, colorectal cancer
4
LUS, tumor arising from lower uterine segment
5
E, endometrioid carcinoma; C, clear cell carcinoma; M, mixed endometrioid and sarcomatoid carcinoma
2
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Given these findings in the convenience sample cohort, these characteristics were
also evaluated in the population–based cohort (Table 13). As in the convenience sample
cohort, there was no statistically significant difference between the clinical characteristics
of median age of diagnosis and family history of EC or CRC. The significant association
of diabetes between unmethylated and methylated MLH1 found in the convenience
cohort was not present in the population-based cohort. This suggests that the statistically
significant difference found in the convenience sample may be due to Type I error.
Investigation of tumor-specific characteristics revealed no statistically significant
differences between the two groups with respect to histology, FIGO stage, endometrioid
grade, lymphatic/vascular space invasion, tumor location, median tumor size or depth of
myometrial invasion. The statistically significant difference of deep myometrial
invasion found among unmethylated tumors in the convenience sample cohort may be a
result of Type I error or the inherent biases of the endometrial cancer cases used to
generate the convenience sample.
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Table 13. Patient and tumor characteristics for EC in the consecutive, unselected cohort
with IHC loss of MLH1, stratified by presence or absence of MLH1 promoter
methylation.

Patient Characteristics
Age
Median age at diagnosis
Age range
Age
< 50
≥ 50
Family History of EC1
Family History of CRC2
History of Diabetes
Meets SGO Criteria
Tumor Characteristics
Histology
Endometrioid
Non-Endometrioid
FIGO Stage3
I & II
III & IV
Endometrioid Tumor Grade
1 or 2
3
Median depth of myometrial
invasion (mm)4
0 mm
< 50% myometrial invasion
≥ 50% myometrial invasion

Methylated MLH1
n (%)

Unmethylated MLH1
n (%)

P - value

63
49-92

62

0.235

42-79

1 (1.4)

4 (26.7)

71 (98.6)

11 (73.3)

5 (7.1)
5 (7.0)
16 (22.2)
6 (8.5)

3 (21.4)
3 (20.0)
6 (40.0)
6 (40.0)

0.123
0.140
0.192
0.005

70 (97.2)
2 (2.8)

13 (86.7)
2 (13.3)

0.136

57 (79.2)
15 (20.8)

13 (86.7)
2 (13.3)

0.725

59 (81.9)

13 (18.1)

12 (80.0)
3 (20.0)

10 (13.9)
41 (56.9)
21 (29.2)

3 (20.0)
7 (46.7)
5 (33.3)

0.003

> 0.999

0.736

39 (54.9)
8 (53.3)
> 0.999
Lymphatic/vascular space
invasion
Tumor location
Corpus
14 (93.3)
0.437
70 (97.2)
Lower uterine segment
1 (6.7)
2 (2.8)
Largest Median Tumor
Dimension (cm)
3.5
0.547
4
1
EC, endometrial cancer
2
CRC, colorectal cancer
3
FIGO stage I and II denote endometrial carcinomas confined to the uterus. FIGO stages III
and IV represent extra-uterine spread of tumor.
4
Depth of myometrial invasion ≥ 50% total myometrial thickness is associated with increased
risk of lymph node metastasis
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Specific Aim 3. Simplified Cost Analysis
Based on the data presented in Tables 5-9, it was determined that universal tumor
testing identified the greatest number of PLS EC cases. However, tissue testing of all
patients could be a cost-prohibitive process. To investigate this further, a simplified costeffectiveness analysis was performed using the cohort of 412 endometrial cancer patients.
SGO Criteria were applied to the unselected cohort of 412 EC cases, identifying
97 women meeting criteria for further evaluation through tissue testing and genetic
counseling, resulting in a total cost of $93,529.08 (Figure 12, Table 14). Of these 97
identified by the SGO model, 15 are PLS as defined by tissue testing. The total cost per
PLS case detected in the SGO model was $6,143.21. It is estimated that 4-11 of these 15
PLS cases would have a germline mutation detected based on germline mutation
detection rates among those with positive tumor testing results of 25-75%.
The average number of FDRs for those meeting SGO criteria was 5.3. Based on
this and the range of estimated germline mutation rates among PLS EC cases, 21-48
FDRs would be eligible for single site gene mutation analysis and enhanced LS
screening. The estimated costs for screening both PLS cases and their FDRs in this
strategy is $3,055.46-$6,423.55 per case based on germline detection rates of 25-75%
(Table 14).
Applying the universal tumor testing model identified 43 EC patients warranting
further work-up through genetic counseling and germline testing (Figure 13). The total
cost of this screening strategy was $256,726.36, with cost per PLS case identified of
$5,970.38. It is estimated that 11-32 of these 43 patients would have a positive germline
mutation (Table 14).
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The average number of FDRs for those included in the universal tumor-testing
model was 5.5. Based on this and the range of estimated germline mutation rates among
PLS EC cases, 60-176 FDRs would be eligible for single site gene mutation analysis and
enhanced LS screening. The estimated costs for screening both PLS cases and their
FDRs in this strategy is $3,003.35-$6,526.52 per case based on germline mutation
detection rates of 25-75% (Table 14).
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412 EC Cases

Meets SGO
Criteria
N = 97

Does Not Meet
SGO Criteria
N = 315

GC and IHC

Intact Nuclear
Staining
Sporadic EC
N = 76

Loss of Nuclear
Staining of at
least 1 protein
N = 21

GC Follow-Up
Loss of MSH2,
MSH6, or PMS2
PLS EC
N=8

Loss of MLH1
MLH1 promoter methylation assay

GC Follow-Up
Germline Testing

Methylated MLH1
Sporadic EC
N=6

GC Follow-Up
Results Disclosure

GC Follow-Up

Unmethylated MLH1
PLS EC
N=7
GC Follow-Up
Germline Testing
GC Follow-Up
Results Disclosure

Figure 12. Cost analysis schema utilizing SGO 5-10% Clinical Criteria as a screening
model.
1. GC, Genetic Counseling
2. PLS, Probable Lynch Syndrome
3. There was one case in which MLH1 promoter methylation did not work and this was included in the
cases that would go on to receive genetic counseling and germline testing.
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412 EC Cases
Immunohistochemistry for MMR proteins

Loss of Nuclear Staining of
at least 1 MMR Protein
N = 118

Loss of MLH1
N = 90

Loss of MSH2,
MSH2, PMS2
PLS
N = 29
GC Follow-Up
Germline Testing

Intact Nuclear Staining for all
MMR Proteins
Sporadic EC
N = 293

MLH1 promoter methylation assay

Methylation
Present
N = 72

GC Follow-Up
Disclosure of results

*

Methylation
Absent
N = 15
GC Follow-Up
Germline Testing
GC Follow-Up
Disclosure of results

Figure 13. Cost analysis schema utilizing universal tumor testing via
immunohistochemistry and MLH1 methylation analysis when indicated
1. GC, Genetic Counseling
2. PLS, Probable Lynch Syndrome
* There were three cases in which MLH1 methylation was unsuccessful. One case met clinical referral
criteria and was included in genetic counseling decision tree costs; the other two cases had no risk factors
for LS and were not included in the genetic counseling costs with this model.
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Table 14. Comparison of direct Medicare costs associated with SGO Criteria and
universal tumor testing models.
SGO

Universal

Endometrial Cancer Cases (N = 412)
# pts who undergo IHC testing

97

412

# pts who have loss of expression of IHC

21

118

# pts who undergo MLH methylation testing

13

90

# pts seen by genetic counselor

97

43

# PLS identified by strategy

15

43

4, 8, 11

11, 22, 32

$93,529.08

$256,726.36

$6,235.27

$5,970.38

21, 42, 58

60, 121, 176

11, 21, 32

30, 61, 91

$6,432.55

$6,526.52

Cost per LS case identified if 50% of FDRs have a positive
germline mutation:

$4214.43

$4,088.90

Cost per LS case identified if 75% of FDRs have a positive
germline mutation:

$3,055.46

$3,003.35

# PLS estimated to have positive germline test
(Detection rates of 25%, 50%, and 75% germline detection)
Estimated Costs for Screening Strategies
Cost to Screen 412 EC Cases
Average cost per PLS case detected
First degree relatives (FDRs)
# FDRs eligible for germline testing if 25%, 50%, or 75% of
PLS cases have an identifiable germline mutation
Assuming 50% of PLS cases have an identifiable germline
mutation:
# of FDRs who will be germline positive for LS if 25%,
50% or 75% inherit the same mutation
Estimated Costs For Screening Including both PLS and
FDRs (Assuming 50% of PLS have germline mutation)
Cost per LS case identified if 25% of FDRs have positive
germline mutation:
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Next, we calculated the incremental cost effectiveness ratio (ICER) using both
MD Anderson Cancer Center Costs and Medicare costs (Table 15). The calculations
assumed that 50% of PLS patients tested would have a germline mutation detected and
varied the number of FDRs having an identifiable germline mutation between 25-75%.
Comparing SGO Criteria to no screening at all, the ICER using Medicare costs vary
between $3,055.46/LS case (assuming 75% of FDRs are germline positive) and
$6,432.55/LS case (assuming 25% of FDRs will be germline positive). Using MD
Anderson costs, the ICERs vary between $3,202.67/LS case and $6,742.46/LS case. The
SGO Criteria model costs an additional $3,000-$7,000 more per LS case identified than
doing no screening at all.
Comparing the universal testing model to SGO Criteria, the ICER using Medicare
costs vary between $2,974.89-$6,580.62/LS case, and the MD Anderson costs vary
between $2,859.95-$6,326.56 /LS case. This means that universal testing costs an
additional $2,800-$6,600 more per LS case than using SGO Criteria.
There is not a universally accepted ICER value that is interpreted as a favorable or
unfavorable value. The ICER is one component of many factors that a health care
administrator or provider can use to determine which intervention strategy would work
best for his/her practice. In this cohort, one could choose to utilize the SGO criteria
model and spend $2,859.95-$6,326.56 per LS case to identify 4-11 germline Lynch
Syndrome mutations in a population of 412 EC cases and potentially impact 21-58 FDRs.
For an additional $2,800-$6,600 investment per LS case identified in the universal tumor
testing model, 11-32 germline Lynch Syndrome mutations would be identified and 60-
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176 FDRs could be impacted. This type of information can help to determine which
strategy best benefits the specific patient population being examined.
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Table 15. Incremental cost effectiveness ratios (ICER) using direct MDACC institutional costs and direct Medicare costs.

If 75% of FDRs have
positive germline tests
No screening
SGO screening
Universal screening
If 50% of FDRs have
positive germline tests
No screening
SGO screening
Universal screening
If 25% of FDRs have
positive germline tests
No screening
SGO screening
Universal screening

# LS cases
identified
(pts + FDRs)

MDACC Costs
($)

MDACC ICER
$/case

Medicare Costs
($)

Medicare
ICER, $/case

0
40
113

$0
$122
$336,883.14

$0/case
$3,202.67
$2,859.95

$0
$122,218.44
$339,379.04

$0/case
$3,055.46
$2, 974.80

0
29
83

$0
$128,106.68
$336,883.14

$0/case
$4,417.47
$3,866.23

$0
$122,218.44
$339,379.04

$0/case
$4,214.43
$4,021.49

0
19
52

$0
$128,106.68
$336,883.14

$0/case
$6,742.46
$6,326.56

$0
$122,218.44
$3339,379.04

$0/case
$6,432.55
$6,580.62
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Discussion
Endometrial Cancer Patient Population
The EC population used for this study is derived from a large NCI designated
cancer center so there exists a potential for referral bias. However, published data from a
large, national epidemiologic analysis of 161,513 EC cases show that the MDACC EC
population is comparable in terms of baseline clinicopathologic characteristics (59).
Table 16 shows selected characteristics including the number diagnosed at age < 50,
endometrioid histology, and early stage disease between our population and the overall
U.S. population. The greatest difference between the two groups is that there is a higher
proportion of women with grade 2 and 3 tumors in the MDACC population. Despite
these differences, there are no published data stating that Lynch Syndrome associated
endometrial tumors occur preferentially within a certain grade of tumor, so it is
reasonable to believe that the MDACC data can be generalized to other endometrial
cancer patient populations.
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Table 16. Clinicopathologic data of EC Cases for MD Anderson Cancer Center
and U.S. Population.

Diagnosed at age < 50
Histology
Endometrioid
Non-endometrioid
Grade
1
2
3
Stage2
I
II - IV

MDACC
% of EC
population
15.2

U.S. Population1
% of EC
population
13.9

82.4
17.6

85.3
14.7

12.3
61.0
26.7

48.7
35.8
16.1

72.8
27.2

74.7
25.3

1

Derived from reference (59)
Data from reference (57) was derived from the SEER database, in which staging is
recorded using the local/regional/distant categories. MDACC surgical staging data is
according to the FIGO staging system. FIGO Stage I and SEER “Local” category both refer
to disease limited to the uterus. Direct comparisons cannot be made for other FIGO stages.
2
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In addition to having comparable overall EC demographics, the results of the
immunohistochemical and MLH1 analyses are comparable to both national and
international published data. A study by Backes et al. involved performing
immunohistochemical analysis for expression of MLH1, MSH2, MSH6, and PMS2 on all
tumors in a series of 140 unselected, endometrial cancers. Tumors with intact nuclear
staining were considered sporadic, and tumors with absent MSH2 and/or MSH6 were
referred for genetic counseling. MLH1 promoter methylation analysis was not performed.
For patients with tumors exhibiting loss of MLH1 and/or PMS2, those diagnosed at age >
60 years and no FDRs with endometrial or colorectal cancer received no further follow
up, and those younger than age 60 years or having FDRs with EC or CRC received
referral for genetic counseling. Their study showed that 21.4% of all EC tumors
exhibited IHC nuclear loss of at least one MMR protein (60). A similar, populationbased study was undertaken by Leenen et al.in which 183 sequential, unselected EC
tumors of women diagnosed at ≤ 70 years underwent both MSI and IHC testing.
Individuals with MSI-H tumors and absent IHC expression of MSH2, MSH6, or PMS2
were referred for genetic counseling. MSI-H tumors with IHC loss of MLH1 underwent
MLH1 methylation analysis, and those with absent methylation were referred to genetic
counseling. Their study found a rate of 23.5% of IHC loss among all EC tumors, and
96.9% of tumors with IHC loss of MLH1 were methylated (34). A summary of these
published findings, including data from our study, are summarized in Table 17. These
findings support the idea that the results of this thesis research are potentially
generalizable to other endometrial cancer patient populations.
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Table 17. Comparison of MD Anderson results to similarly designed, population-based
endometrial cancer national and international studies.
MDACC1
N = 408
28.9

Ohio State2
N = 140
21.4

Netherlands3
N = 179
23.5

% MLH1 Loss

22.0

17.1

17.9

% methylated
MLH1 promoter

82.7

Not performed

96.9

% with PLS EC

10.5

Estimate (7.7)4

6 (3-11)

% IHC Loss

1: MDACC: MD Anderson Cancer Center
2: (60)
3: (34)
4: Ohio State calculation of % PLS is based on an approximate 80% methylation rate of tumors with IHC
loss of MLH1.
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SGO Clinical Criteria
Society of Gynecologic Oncology clinical screening criteria for Lynch Syndrome
among endometrial cancer patients was codified in 2007. As can be seen from Tables 1
and 2, these criteria strongly resemble Amsterdam II and revised Bethesda Guidelines.
Thus, many of the clinical recommendations for identifying endometrial cancer patients
at elevated risk for having Lynch Syndrome have been extrapolated from colorectal
cancer registries.
Ryan et al. evaluated Amsterdam II, revised Bethesda, and SGO criteria in a
cohort of 76 endometrial cancer cases with known Lynch Syndrome germline mutations
identified through databases from the British Columbia Familial Cancer Registry and
Mount Sinai Hospital Familial Gastrointestinal Cancer Registry. They found that SGO 510% criteria identified 93% of EC cases with known germline mutations. The detection
rates of MLH1, MSH2, and MSH6 using SGO 5-10% criteria were 94%, 94%, and 88%,
respectively. There were no PMS2 mutations in this patient population. They concluded
that SGO 5-10% Criteria performed best in identifying germline Lynch Syndrome
mutations in endometrial cancer cases (13). These criteria have not been validated in
either a clinic-based referral population or a population-based setting.
The predominance of MLH1 and MSH2 mutation carriers within Lynch Syndrome
registries, including the three in which mutation carriers from the Ryan et al. study were
derived, results in validation of existing criteria for these types of mutations. The relative
paucity of MSH6 and PMS2 mutation carriers in Lynch Syndrome registries suggests that
these mutations are rare or that they are missed by current screening strategies. Work by
Senter and colleagues investigated 99 individuals with immunohistochemical loss of
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PMS2 in 99 Lynch Syndrome associated tumors (91 CRC, 5 EC, 1 gastric, 1 small bowel,
and 1 transition cell of renal pelvis) and performed PCR-based mutation analysis. Cases
were obtained both through clinic-based screening criteria as well as in the populationbased setting; 8/99 (8.1%) were endometrial cancers. They found that 62% of cases with
IHC loss of PMS2 had a detectable PMS2 germline mutation. Among germline carriers,
9.1% met Amsterdam II guidelines, 65.5% met revised Bethesda Guidelines, and 25.5%
met no published clinical criteria (58). The fact that only a quarter of germline PMS2
mutation carriers meet published clinical guidelines supports the possibility that its
prevalence in Lynch Syndrome associated cancers may be under-estimated.
Published data on cumulative cancer risk to age 70 among individuals with known
germline MSH6 mutations have been shown to be less than that for MLH1 and MSH2
mutations carriers (61). Hendriks et. al examined the lifetime cancer risks among 146
individuals with germline mutations in MSH6 who met Amsterdam II criteria, compared
to a cohort of MLH1 and MSH2 germline mutation carriers. For male MSH6 mutation
carriers, the cumulative colorectal cancer risk is 69%; for female MSH6 mutation carriers,
the cumulative colorectal cancer risk is 30% and the cumulative risk for endometrial
cancer is 70%. Additional clinical screening criteria were not evaluated in their study,
but MSH6 mutations carriers have been found to not meet standard clinical criteria in
several previously published studies (62,63).
The performance of SGO Criteria in our population of identifying individuals at
elevated risk (IHC loss of MLH1, MSH2, MSH6 or PMS2 with absence of MLH1
promoter methylation) is consistent with these other published results. Clinical criteria
perform best at detecting those with IHC loss of MLH1 or MSH2, but perform quite
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poorly at identifying those with loss of MSH6 or PMS2. Based on the findings of our
study and other published literature, clinical criteria preferentially identify only a subset
of patients with endometrial cancer at risk for having Lynch Syndrome.
The underlying cause for an older median age at diagnosis for MSH6 or PMS2
mutations has not been elucidated. Work by Chen and colleagues examined single
nucleotide polymorphisms (SNPs) of genes playing key roles in the cell cycle in a
population of individuals with identifiable germline Lynch Syndrome mutations
identified through a CRC registry. They utilized CART analysis and found that certain
SNPs were associated with either earlier median onset of CRC diagnosis or a later age of
onset. One SNP association they found associated with older age at diagnosis was
individuals with wildtype E2F2 and AURKA variant had a median age of diagnosis of 70
(64). It is possible that genetic variants may also play a role in endometrial cancers in
individuals harboring MSH6 and PMS2 mutations that might explain the older median
age at diagnosis in this subgroup.
In the colorectal cancer literature, there have been modifier genes identified that
may account for some of the variability seen among germline Lynch Syndrome mutation
carriers. Wijnen and colleagues explored the role of established SNPs associated with
CRC (8q24.21, 18q21.1, 15q13.3, 8q23.2, 10p14, and 11q23.1) in a population of 675
patients with germline Lynch Syndrome mutations. They found that an individual with
either the SNP rs3802842 (11q23.1) or rs16892766 (8q23.3) as well as a germline Lynch
Syndrome mutation had a greater risk for developing CRC than individuals without these
SNPs (65). This work was validated by Talseth-Palmer et al. in a cohort of 684
individuals with confirmed germline mutations in Lynch Syndrome genes. They found
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the association between the SNPs on 11q23.2 and 8q23.2 was valid for only those with
MLH1 mutations (66). Talseth-Palmer et al. subsequently performed a combined
analysis of data derived from the Wijnen et al. and Talseth-Palmer et al. studies to further
characterize the role of these SNPs among MLH1 germline mutation carriers. Among
individuals with Lynch Syndrome, they found the SNP at 11q23.1 was associated with an
increased CRC risk compared to individuals without Lynch Syndrome. Additionally,
Lynch Syndrome mutation carriers with the SNP at 8q23.2 were diagnosed at earlier ages
(67). These studies call attention to modifier genes and their impact on the variability
seen within colorectal cancer among Lynch Syndrome patients. There are currently no
published studies examining the role of modifier genes among the endometrial cancer
cases in patients with Lynch Syndrome.
SGO Clinical Criteria among Endometrial Cancer Patients with IHC loss of MLH1
Approximately 15-20% of all endometrial and colorectal tumors will exhibit IHC
loss of MLH1; however, between 60-90% of these tumors are considered sporadic rather
than hereditary because they have epigenetic silencing of the MLH1 promoter through a
methylation event (26-28,30). Despite the body of research that supports performing the
PCR-based MLH1 methylation assay when evaluating tumors exhibiting IHC loss of
MLH1, it is not routinely performed in the published literature describing clinical
screening algorithms for LS (33-36). Though the reasons for this are not entirely clear,
one possible explanation could be that some clinical laboratories do not have access to
PCR-based testing or only have access to simpler PCR analyses such as hot-spot
sequencing for mutational analyses.
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This sub-analysis was designed to determine if any clinical, pathologic, or clinical
screening tool could effectively replace using the PCR-based MLH1 methylation analysis
in the evaluation of endometrial cancer patients for possible Lynch Syndrome. Therefore,
our evaluation was limited to ECs with loss of MLH1 in our convenience sample cohort.
From the data presented in Tables 10-13, we conclude that no combination of clinical,
pathologic, or clinical criteria is superior to MLH1 methylation in evaluating tumors with
IHC loss of MLH1.
Several published reports support that the prevalence of MLH1 methylation
increases with age (31,32). An investigation by Whelan et al. examined 40 endometrial
carcinomas with immunohistochemical loss of MLH1 and compared their
clinicopathologic information to 40 endometrial carcinomas with intact MLH1. It is
unclear if their endometrial cases were recruited from a population-based setting or from
a clinic-based referral population. They found a significant difference between the age of
endometrial cancer diagnosis in MLH1 methylated (mean age 56.1 years) versus
unmethylated (mean age of 65.4 years) cases (31). Work by Zauber and colleagues also
investigated MLH1 methylation in the endometrial cancers, examining differences
between women diagnosed at less than age 50 compared to women diagnosed at greater
than or equal to age 50. They found that 61.9% of MSI-H tumors were unmethylated in
the younger group with a median age of diagnosis of 42.6, and 17.1% of MSI-H tumor
were unmethylated in the older group with a median age of diagnosis of 64.6. As can
been seen in tables 10 and 13, we found no statistically significant difference in either our
convenience sample cohort or population-based cohort in terms of median age of
diagnosis between methylated and unmethylated MLH1 EC tumors. Our data agree with
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other published data that MLH1 methylation of EC tumors increases with increasing age,
but age does not accurately predict methylation status.
Previous investigators have demonstrated that there are macroscopic and
microscopic pathologic features of endometrial carcinomas that correlate with a diagnosis
of Lynch Syndrome. Westin et al. examined endometrial carcinomas arising from the
lower uterine segment (LUS) and found that 29% (10/35) were Lynch Syndromeassociated (44). Among these 10 cases, 9/10 had loss of MSH2 by IHC and 1 had loss of
MLH1 without MLH1 methylation. In both our convenience sample and populationbased cohorts, LUS tumor location did not distinguish between the methylated and
unmethylated MLH1 tumors with IHC loss of MLH1.
When immunohistochemistry for DNA mismatch repair proteins is used as part of
the evaluation for Lynch Syndrome in endometrial or colorectal cancers, absence of
MLH1 immunohistochemical protein expression is a poor predictor for a germline
mutation (38), as most of these tumors will also have somatic methylation of the MLH1
gene (sporadic carcinoma), rather than germline mutation (Lynch Syndrome). Further,
our sub-analysis supports that clinical and pathologic screening criteria poorly predict
which endometrial cancers with IHC loss of MLH1 are likely to have presence or absence
of MLH1 methylation. In our convenience sample cohort of 54 endometrial cancer cases
with immunohistochemical loss of MLH1, 14/54 cases would be candidates for germline
MLH1 testing. SGO criteria correctly identifies 10/14 unmethylated tumors. If SGO
criteria were solely used without the MLH1 methylation assay, 22/54 patients would
undergo germline testing for MLH1, thereby subjecting 12 women to unnecessary and
expensive germline testing. We conclude that MLH1 promoter methylation testing is a
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valuable component of clinical laboratory tumor testing for Lynch Syndrome among
patients with endometrial cancers exhibiting immunohistochemical loss of MLH1.
Historical Risk Factors for Lynch Syndrome and Generation of New Criteria
From the data presented in this thesis, historically accepted risk factors such as
young age at cancer diagnosis, strong family history, and non-obese BMI (< 30 kg/m2)
are not as useful at delineating sporadic endometrial cancer from Lynch Syndrome
associated cases. Several studies have shown that the prevalence of Lynch Syndrome due
to defects in all DNA MMR genes is increased in women diagnosed with endometrial
cancer at age younger than 50 years. In the study by Lu et al., 11% (11/100) of women
presenting with endometrial cancer at age younger than 50 years had tumor testing results
suggestive of Lynch Syndrome and 9% had an identifiable germline mutation. Of the 9
women with identifiable germline mutations, 7 had an MSH2 mutation, 1 had an MLH1
mutation, and 1 had an MSH6 mutation (56). In a similar study performed by Walsh et
al., 18% (26/146) of women with endometrial cancer diagnosed at less than age 50 years
had molecular diagnostics testing (IHC, MSI, and MLH1 methylation) consistent with
Lynch Syndrome. In their study, there were 6 MLH1 13, MSH2, and 7 MSH6 PLS
tumors. In both of these studies, those with presumed MSH2 mutations were the most
likely to present with Lynch Syndrome associated endometrial cancer at a younger age
(68).
Obesity is an important determinant of endometrial cancer risk in the sporadic
patient population (69). The relationship between BMI and Lynch Syndrome associated
endometrial cancer has been investigated previously in patients younger than age 50 as
well as in cohorts consisting of all ages. Lu et al. found that a median BMI of 27.6
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among Lynch Syndrome endometrial cancer cases was significantly lower than the
median BMI of 37.5 among sporadic cases in a set of EC patients diagnosed at age less
than 50. The sensitivity and specificity of BMI ≤ 30 for predicting Lynch Syndrome was
56% and 65%, respectively (56). Another study by Schmeler et al. found that 56% of
188 EC patients under the age of 50 were obese (BMI ≥ 30.0), and all six patients with
Lynch Syndrome were either normal weight or overweight (BMI 25.0-29.9) (70). In one
additional study, McCourt et al. evaluated microsatellite instability in a series of 473
sequential endometrial carcinomas and found that patients with MSI-high tumors had a
significantly lower BMI (30.3) than those with microsatellite-stable tumors (32.7) (29).
While these studies support that BMI may play a role in differentiating between sporadic
and Lynch Syndrome associated endometrial tumors, the results from our study reveal no
statistically significant difference between BMI < 30 and a diagnosis of PLS EC. This
could be due in part to the increases in obesity in the U.S. population, which may obscure
a previously significant differentiator between sporadic and Lynch Syndrome associated
tumors. Also, the median age of EC diagnosis in our unselected patient cohort was well
above 50 (age 61). It is possible that BMI is a distinguishing feature only in younger EC
patients.
A strong family history of certain cancers played a pivotal role in the initial
identification and characterization of Lynch Syndrome and continues to be a principal
component in widely accepted clinical screening algorithms such as Amsterdam II,
revised Bethesda guidelines, MMRPro, PREMM, MMRPredict, and SGO Criteria.
Unfortunately, family history is not perceived to be as helpful as it once was. In 2009,
the EGAPP working group de-emphasized the role of family history when evaluating
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individuals for risk of Lynch Syndrome, recommending a universal tumor testing
approach. This recommendation was due in part to the poor overall sensitivity and
specificity profiles of clinic-based screening criteria such as Amsterdam II or Revised
Bethesda guidelines as well as suboptimal recording patient history by clinicians (46).
We found no statistically significant differences in family history of EC or CRC between
our PLS EC cases and sporadic EC cases. Further, the majority of all patients in our
cohort did not have a family history of either tumor. Additionally, average family size in
the 2000sis not the same as it was when Lynch Syndrome was first characterized in the
early 1900s. In Dr. Warthin’s original Family G, there was a male proband with 10
children. In our current cohort, the average number of siblings among our endometrial
cancer cases was 3.4, and the average number of children was 2.1. As family sizes
decrease, the probability of detecting a high proportion of cancers also decreases. The
utility of family history in identifying patient’s at risk for hereditary cancer syndromes
may be decreasing in the current generations.
Further analyses to modify SGO Criteria or generate new clinical criteria to better
identify Lynch Syndrome among endometrial cancer patients could not be generated
from our cohort of 408 cases. In order to capture the maximal number of women with
Lynch Syndrome who present with endometrial cancer, it may be necessary to adopt a
universal tumor testing approach, as is increasingly being recommended for colorectal
cancer patients.
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Cost Analysis
There are few published cost analyses that evaluate screening methodologies for
Lynch syndrome in women presenting with endometrial cancer. Kwon et. al evaluated
several different screening strategies using a Monte Markov simulation model to evaluate
the costs (IHC for DNA MMR genes, genetic counseling, germline testing, colonoscopy
for detected LS cases, and average lifetime cost of CRC treatment) relative to the benefits
(life expectancy) and generated an ICER for each screening strategy. They found that
triaging all women with endometrial cancer who had a first-degree relative having a
Lynch Syndrome-associated cancer at any age with immunohistochemistry was the most
cost effective method (33).

If we were to apply this screening strategy to our existing

population-based cohort of 412 EC cases, 60 (14.6%) individuals would undergo
immunohistochemical analysis, with 9 of these having tumor testing suggestive of Lynch
Syndrome. This leaves 34 individuals with tumor testing consistent with Lynch
Syndrome that would go undiagnosed using the Kwon et. al screening strategy. Though
determined cost effective by Kwon’s analysis, one must determine if the cost savings is
worth the potential health-related implications of missing the diagnosis in 34 individuals
and the impact this might have on both them and their first-degree relatives.
Work by Dinh and colleagues thoroughly evaluated screening strategies for
colorectal and endometrial cancer using a Monte Carlo simulation of 100,000
hypothetical individuals modeled after the U.S. population starting at age 20. They
compared direct medical costs for risk-assessment based screening (PREMM1,2,6) starting
at different age at diagnosis and compared this to universal 4-gene mutation sequencing
of all individuals. Unique to their study, they evaluated an individual’s risk prior to the
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development of EC or CRC and the detection/prevention of these cancers was also
incorporated in to costs/benefits. They found that risk-assessment of all individuals
between the ages of 25-35 with PREMM1,2,6 followed by genetic testing for those with a
risk score of ≥ 5 % was the most cost-effective strategy (71). At the time of this
publication, the study by Mercado et al evaluating the PREMM1,2,6, MMRPro, and
MMRPredict algorithms in endometrial cancer had not yet been published. Dinh’s study
utilized PREMM1,2,6 as its sole risk-assessment strategy and found it to have an area
under the curve (AUC) of 0.77; an AUC greater than 0.80 is deemed favorable. None of
these screening strategies have been validated in the PMS2 germline mutation population.
In our analysis, the cost per PLS case identified using a universal tumor testing
strategy comprised of immunohistochemistry and MLH1 methylation analysis when
indicated is $5,970.38. While this could be considered a favorable cost, creating an ideal
cost analysis strategy is difficult. As can be seen by both our work and the work from
others described above, there can be immense shift in costs as different assumptions and
costs are added or removed from the models. The variation in perspective from different
physician groups, different cancer patient populations, and different societies can also
influence how such cost analyses are perceived.
Compliance with Published Screening Criteria Guidelines
As we strive to identify the best model for identifying Lynch Syndrome among
endometrial cancer patients, it is important to be aware of the compliance of physicians
with meeting referral guidelines. In our analysis, only 30% of endometrial cancer
patients meeting institutional referral criteria actually received a recommendation to see a
genetic counselor. This low rate is comparable to other published studies examining
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compliance with screening recommendations. In the BRCA population, Meyer et al.
examined the medical records of 3,765 ovarian cancer patients, of which 23.8% were
determined to be at substantial risk for having a BRCA mutations. Only 12% of these
patients were referred to genetic counseling at the beginning of their study, and this
number increased to 48% following a clinic-based intervention strategy. Despite a
dramatic improvement in referral habits over the course of the study, 50% of women at
substantial risk were not offered genetic counseling at the end of the study period (72).
Grover et al. evaluated the genetic counseling referral rate among colorectal cancer
patients who met revised Bethesda Guidelines. In their cohort of 387 patients, 75 (19%)
met referral criteria, but only 13 (17%) of these patients received a referral for genetic
counseling and further risk assessment (73).
These data, coupled with results from our analysis, show a very poor compliance
with published hereditary cancer syndrome screening guidelines. If published guidelines
have excellent sensitivity and specificity for detecting disease, it would seem reasonable
to create systems within the clinic-based setting to improve history-taking and referral
rates. In the case of SGO Criteria, it may not be as beneficial to invest resources in
improved referral when only a 32% of patients at elevated risk are identified. There has
been one study in the CRC literature examining referral rates after implementation of a
universal tumor testing regimen comprised of microsatellite instability testing and
immunohistochemistry in all CRC cases. Heald and colleagues evaluated three different
referral programs: 1) test results were sent only to the surgeon; 2) test results went to both
the surgeon and genetic counselor, and the genetic counselor would send a follow up email to the surgeon; and, 3) test results went to both the surgeon and genetic counselor,
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and the genetic counselor would contact the patient and arrange a follow-up appointment.
They found that the multidisciplinary approach (Options 2 and 3) resulted in 10-fold
quicker follow-up for patients when compared to a single individual approach (Option 1).
When the genetic counselor was the primary point of patient follow-up (Option 3), 100%
of patients meeting referral criteria received a referral, whereas only 55% of those in
Option 1 and 82% of those in Option 2 received a referral (47).
Study Limitations
This study has several limitations. First, it is a retrospective study and all
clinicopathologic data was abstracted from the electronic medical record. This
particularly affects acquisition of family history. Ideally, a full 3-generation family
history is obtained from a genetic counseling professional and patient’s fulfillment of
clinical screening criteria is based on that assessment. Many patients have recall bias or
vague ideas of the original location of a family member’s tumor. For example, they
know that a family member had a gynecologic cancer but unsure of whether it was cervix,
uterine, or ovary. Our study delineated whether or not a patient met criteria based on selfreported history and genetic counseling data when available.
Additionally, we have based our assessment of SGO Criteria on its ability to
detect elevated-risk EC tumors defined by those with IHC loss of a DNR MMR protein
(absence of MLH1 methylation when indicated) and not on its ability to detect germline
mutations. At this point in time, patients have been notified of their tumor testing results
and are in various stages of genetic counseling follow-up. Many previously published
studies have used germline testing results as the “gold” standard. DNA sequencing is
known for high sensitivity in detecting point mutations and small insertions, but the large
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deletions, insertions, or gene arrangements are not as easily detected (48). Thus, when a
patient has tumor molecular diagnostic testing results suggestive of LS but negative
germline testing, the question remains whether or not that patient truly has Lynch
Syndrome.
Of the myriad of studies using molecular diagnostics testing to evaluate for Lynch
Syndrome, there is only one publication that addresses tumor test positive/germline
negative cases. Rodriguez-Soler et al. evaluated 1,705 consecutive colorectal patients for
Lynch Syndrome by performing MSI and IHC testing on all tumors (74). They examined
clinicopathologic data of patients as well as age-adjusted incidence of cancer in family
members between sporadic, tumor test positive/germline negative, and germline positive
individuals. They found that germline positive patients were more likely to fulfill revised
Bethesda guidelines than the tumor test positive/germline negative. Additionally, they
found that the familial incidence of colorectal cancer was greatest in germline mutation
carriers, next highest in tumor test positive/germline negative, and least in families with
an individual with a sporadic colorectal cancer. Risk of endometrial cancer and other
Lynch Syndrome associated tumors were not included in this study. More investigation
needs to be done to determine the optimal approach to managing tumor test
positive/germline negative patients, particularly since published guidelines support
universal tumor testing of all colorectal cancers.
Lastly, the assumptions built in to our simplified cost analysis help to generate an
estimate of direct costs, but it does not encompass many other factors that can be part of
costs/benefits of any healthcare decision. To begin with, our model assumes a 100%
genetic counseling referral rate for endometrial cancer patients meeting SGO Criteria,
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when published rates for various criteria in clinical practice vary from 17-48%. Thus,
costs associated with the SGO model are a higher estimate than what would likely occur
in reality (72,73). Our model also assumes that all patients either meeting SGO Criteria
or with tumor testing suggestive of Lynch Syndrome will accept referral for genetic
counseling and/or germline testing. Compliance of endometrial cancer patients with
genetic counseling referrals to evaluate for Lynch Syndrome may not be 100%. In a
single institution study, Backes and colleagues surveyed the 47/384 EC patients who met
institutional criteria for genetic counseling referral through a mailed questionnaire and
follow-up phone call. Immunohistochemistry was performed on all endometrial cancers
and referral for genetic counseling was recommended for: 1) individuals with loss of
MLH1/PMS2 diagnosed at less than age 60; 2) individuals with loss of MLH1/PMS2
with a family history of a Lynch Syndrome associated tumor in a first-degree relative; 3)
any individual with loss of MSH2/MSH6, MSH6 only, or PMS2 only. A total of 26/47
(55.3%) responded to the questionnaire and 20/26 (77%) stated that they had been
referred to see a genetic counselor. Despite referral, only 9/20 (45%) saw a genetic
counselor and 8/9 underwent germline testing. They found the two most common
reasons for not seeing a genetic counselor were lack of insurance/cost for seeing a genetic
counselor and anxiety related to the results (75).
There are many more costs that can be incorporated into a cost analysis, such as
the cost of more frequent colonoscopy in LS cases, cost of colonoscopy complications,
the cost of failing to prevent a colorectal cancer in an undetected LS case, the cost of a
preventable EC or CRC in first-degree family members, and the emotional “cost”
associated with the anxiety of testing. There are also different measures of effectiveness
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that could be used such as number of cancers prevented or cancers diagnosed at an early
stage. Referring to Figure 4, it is easy to see how subtle changes in the assumptions and
inputs into the model can cause more dramatic changes in ICER, our metric for cost
effectiveness comparison. Lastly, costs for this analysis were calculated using 2012 U.S.
dollars and 2012 CPT codes. Inflation, CPT codes, and Medicare reimbursements can all
change year to year. Therefore, rather than focusing on absolute costs, for our cost
analysis it is more useful to consider the relative cost between the SGO screening method
and the universal tumor testing method.
Conclusions
This is the first large, single-institution study examining endometrial cancer and
Lynch Syndrome in a population-based fashion with a universal testing model starting
with immunohistochemical analysis of all endometrial tumors. Our evaluation of the
Society of Gynecologic Oncology 5-10% Clinical Criteria’s ability to detect probable
Lynch Syndrome endometrial cancer cases has shown that SGO Criteria identify only a
small subset of PLS EC cases in the population-based setting. Universal tumor testing of
EC (IHC and MLH1 methylation when indicated) is a cost-effective alternative that
detects more individuals at elevated risk, providing more opportunity for cancer
prevention among women and their families.
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